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Abstract
Background: Stearoyl-CoA desaturase 1 (SCD1) is an ER resident enzyme introducing a double-bond in saturated
fatty acids. Global knockout of SCD1 in mouse increases fatty acid oxidation and insulin sensitivity which makes the
animal resistant to diet-induced obesity. Inhibition of SCD1 has therefore been proposed as a potential therapy of
the metabolic syndrome. Much of the work has focused on insulin target tissue and very little is known about how
reduced levels of SCD1 would affect the insulin-producing b-cell, however. The aim of the present study was
therefore to investigate how reduced levels of SCD1 affect the b-cell.
Results: Insulin-secreting MIN6 cells with reduced levels of SCD1 were established by siRNA mediated knockdown.
When fatty acid oxidation was measured, no difference between cells with reduced levels of SCD1 and mock-
transfected cells were found. Also, reducing levels of SCD1 did not affect insulin secretion in response to glucose.
To investigate how SCD1 knockdown affected cellular mechanisms, differentially regulated proteins were identified
by a proteomic approach. Cells with reduced levels of SCD1 had higher levels of ER chaperones and components
of the proteasome. The higher amounts did not protect the b-cell from palmitate-induced ER stress and apoptosis.
Instead, rise in levels of p-eIF2a and CHOP after palmitate exposure was 2-fold higher in cells with reduced levels
of SCD1 compared to mock-transfected cells. Accordingly, apoptosis rose to higher levels after exposure to
palmitate in cells with reduced levels of SCD1 compared to mock-transfected cells.
Conclusions: In conclusion, reduced levels of SCD1 augment palmitate-induced ER stress and apoptosis in the b-cell,
which is an important caveat when considering targeting this enzyme as a treatment of the metabolic syndrome.
Background
Stearoyl-CoA desaturases (SCD:s) are a family of endo-
plasmic reticulum (ER) resident enzymes introducing a
Δ9 double-bond in saturated fatty acids, thereby gener-
ating their monounsaturated counterparts [1]. In mice,
four isoforms of SCD have been characterized, which all
catalyze the same reaction but have somewhat different
substrate specificities [1]. The physiological role of hav-
ing multiple isoforms is not fully understood, but the
different expression patterns and inducibility indicate
exclusive roles for the different isoforms [2]. In humans,
only one functional ortholog to mouse SCD has been
found [3]. In addition, humans express another SCD iso-
form, termed hSCD5, which is unique to primates [4].
Much focus has been directed towards the SCD1
isoform, which is ubiquitously expressed in mouse, and
the major isoform found in liver and adipose tissue [2].
While SCD1 seems to have a protective effect in many
cell types exposed to saturated fatty acids in vitro [5-7],
evidence from SCD1 KO mice and from mice injected
with antisense oligonucleotides against SCD1 has shown
that lack of SCD1 protects the animals from diet-
induced obesity [8,9]. The lack of SCD1 results in higher
energy expenditure, reduced fatty acid de novo synthesis,
decreased expression of lipogenic genes, and increased
insulin sensitivity [8,10]. In human studies, elevated
levels of SCD1 were positively correlated with high tri-
glyceride levels in familial hypertriglyceridemia subjects
[11], increased body mass index, reduced fatty acid oxi-
dation and high plasma insulin levels [12]. It has been
suggested that SCD1 acts as a main molecular switch
between lipolysis and lipogenesis, as increased SCD1
expression precedes the increased expression of other
lipogenic genes in mice fed a diet high in stearate. The
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increase in SREBP-1c and PPAR-g coactivator-1b (PGC-
1b) [13]. Reducing or inhibiting the enzyme has there-
fore been proposed as a novel treatment for obesity,
type-2 diabetes mellitus and related metabolic disorders
[14]. Accordingly, efforts have been made to identify
pharmacological inhibitors of SCD1. In agreement with
results obtained in the SCD1 KO mouse [9], oral admin-
istration of a selective SCD1 inhibitor strongly repressed
the diet-induced weight gain in C57BL6 mice as well as
decreased the desaturation index (oleate/stearate) [15].
Also, the effects of reduced SCD1 were reproduced in
rat models where SCD1 inhibition reduced plasma tri-
glyceride levels and improved insulin sensitivity [16].
Work regarding the role of SCD1 has primarily focused
on insulin target tissue such as liver, muscle and white
adipose tissue. Very little is known about the role of the
enzyme in the insulin-producing pancreatic b-cell and
how reduced SCD1 levels would affect the cell. The aim
of the present study was to test if reducing the levels of
SCD1 had positive effects also on the b-cell, and if so,
by which pathways these effects were mediated.
Results
Fatty acid oxidation and insulin secretion in MIN6 cells
with reduced levels of SCD1
Insulin-producing MIN6 cells with reduced SCD1 levels
were obtained by knocking down (KD) the levels of the
enzyme with siRNA (SCD1 KD cells). Transfection with
SCD1 siRNA efficiently reduced transcript levels, which
were 37% of levels in cells transfected with nonsense
siRNA (mock-transfected cells) 72 hours post transfec-
tion (Fig 1A).
A hallmark of the SCD1 KO mouse is increased fatty
acid oxidation and phosphorylation of AMPK, which are
suggested to contribute to explain the resistance to diet-
induced weight gain in these animals [17]. To test if
these results were reproducible also in MIN6 cells with
lowered SCD1, fatty acid oxidation and phosphorylation
of AMPK were measured in SCD1 KD and mock-trans-
fected cells. No difference in level of fatty acid oxidation
between cells with reduced levels of SCD1 and control
cells could be detected, however (Fig 1B). Also, when
phosphorylated AMPK was measured, similar levels
were obtained in mock-transfected and SCD1 KD cells
(Fig 1C). The SCD1 KO mouse has increased fatty acid
oxidation also when fed a diet rich in saturated fatty
acids [13]. When we measured fatty acid oxidation in
SCD1 KD and mock-transfected cells exposed to palmi-
tate for 24 or 48 hours, no difference between SCD1
KD and mock-transfected cells in levels of fatty acid oxi-
dation could be detected (Fig 1D).
The primary function of the pancreatic b-cell is to
secrete insulin in response to elevated nutrient levels,
primarily glucose. The SCD1 KO mouse has increased
insulin receptor signaling [10]. Insulin receptors are pre-
sent also on the b-cell and it has been shown that
increased signaling potentiates insulin secretion [18]. We
therefore tested if the secreto r yr e s p o n s et og l u c o s ew a s
altered by reducing the levels of SCD1. Glucose-stimulated
insulin secretion rose 3-fold in mock-transfected cells
when increasing the glucose concentration from 2 to 20
mM (Fig 1E). Similar changes were observed in SCD1 KD
cells, however. From the results we concluded that energy
metabolism and function were not altered in MIN6 SCD1
KD cells in contrast to liver cells from the SCD1 KO
mouse [17].
Proteomic analysis on cellular proteins differently
regulated by SCD1 KD
We next used a proteomic approach to identify mechan-
isms by which reduced SCD1 levels affected MIN6 cells.
Cellular proteins obtained from SCD1 KD and mock-
transfected cells were separated, quantified and differ-
ently expressed proteins identified. Knockdown of SCD1
mainly up-regulated proteins involved in protein folding
and degradation (Table 1). Protein disulfide isomerase
(PDI), prolyl 4-hydroxylase and glucose-regulated protein
94 (GRP94), chaperones involved in protein folding in
the ER, were all up-regulated by more than 50% when
SCD1 levels were lowered. Indication of increased
expression of the proteasome was also found as two of its
components, proteasome subunit a type 3 and protea-
some 26 S subunit, were up-regulated by more than 50%
in SCD1 KD cells compared to mock-transfected cells. In
addition, levels of proteins involved in RNA modulation
and serine metabolism were elevated, although the
importance of these proteins was not evaluated.
ER stress response and apoptosis in MIN6 cells with
reduced levels of SCD1
Enhanced chaperone and proteasome expression is part
of the unfolded protein response (UPR), which is elicited
when the ER load is enhanced and un- or misfolded
proteins accumulate. When the UPR is not successful in
alleviating the load on the ER, apoptosis is induced [19].
In b-cells, ER stress mainly connects to apoptosis
through the PERK pathway via its downstream effectors
phosphorylated eIF2a (p-eIF2a) and CHOP. As ER cha-
perones and proteasomal components were up-regulated
after SCD1 knockdown, we hypothesized that PERK sig-
naling would be decreased. When levels of p-eIF2a and
expression of CHOP were measured there was no differ-
ence between SCD1 KD and mock-transfected cells cul-
tured under control conditions (Fig 2). Knockdown of
SCD1 caused a reduction in the cellular levels of cleaved
caspase-3, however.
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transfected cells on UPR could be accounted for by low
levels of ER stress under control culture conditions. We
therefore exposed MIN6 cells to the fatty acid palmitate,
which elicits ER stress and induces apoptosis [20].
Indeed, levels of p-eIF2a rose after 24 hours of palmi-
tate exposure (Fig 3A). Levels of p-eIF2a were higher in
SCD1 KD cells than in mock-transfected cells after 24
and 48 hours of palmitate exposure, however. Phosphor-
ylation of eIF2a precedes the alternative translation of
ATF4, which in turn increases the amount of CHOP. In
agreement with this temporal relationship, levels of
CHOP began to rise after 24 hours of palmitate expo-
sure in both mock-transfected and SCD1 KD cells (Fig
3B). Whereas CHOP levels in mock-transfected cells
increased 3-fold after 48 hours of palmitate exposure,
levels in SCD1 KD cells increased more than 6-fold.
CHOP acts as a pro-apoptotic mediator in the cell, and
increased levels of the protein have been associated with
increased rates of apoptosis [21]. To examine if the
increased levels of CHOP translated into apoptosis, we
measured levels of cleaved caspase-3. Cells with reduced
levels of SCD1 had lower levels of cleaved caspase-3
than mock-transfected cells during the first 8 hours of
exposure to palmitate (Fig 3C). After exposure to the
fatty acid for 24 hours, levels of cleaved caspase-3
increased in both SCD1 KD cells and mock-transfected
cells. In agreement with elevated levels of CHOP, levels
Figure 1 SCD1 mRNA levels, fatty acid oxidation and glucose-stimulated insulin secretion in MIN6 cells transfected with SCD1 siRNA.
MIN6 cells were transfected with siRNA targeted towards SCD1 (black bar) or with nonsense siRNA (Mock; white bar). After 72 hours culture,
SCD1 transcript levels were measured (panel A). Fatty acid oxidation (panel B) and levels of p-AMPK (panel C) were measured 72 hours post-
transfection in mock-transfected and SCD1 KD cells. Fatty acid oxidation was measured after 24 or 48 hours exposure to 0.25 mM palmitate
(panel D). MIN6 cells transfected with mock siRNA or SCD1 siRNA were stimulated with 2 or 20 mM glucose. After stimulation, secreted insulin
was measured (panel E). Results are means ± SEM from 4-6 individual experiments. *P < 0.05 denotes change compared to mock-transfected
cells.
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in mock-transfected cells after 24 hours of palmitate
exposure. In conclusion, reducing the levels of SCD1 in
insulin-secreting MIN6 cells increased ER stress and
apoptotic signaling in response to palmitate.
Discussion
Reduction of SCD1 has beneficial effects in whole ani-
mal studies. The positive role of reducing [6] or comple-
tely removing SCD1 [7] has been linked to increased
fatty acid oxidation and insulin sensitivity, and to a
reduction of fatty acid de novo synthesis. Consequently,
inhibiting SCD1 has been suggested as a potential
therapy for the metabolic syndrome [16]. Administration
of the SCD1 inhibitor GSK993 to a diet-induced insulin
resistant rat model readily improved insulin sensitivity
[16], and a beneficial phenotype has also been seen
in vivo by infusing the animals with antisense oligonu-
cleotides towards SCD1 [8]. In our in vitro model, the
reduction of SCD1 did neither lead to an increase in
fatty acid oxidation under control conditions, nor after
exposure to palmitate for 24 or 48 hours. Also, no dif-
ferences in insulin secretion were observed between
cells with reduced levels of SCD1 and mock-transfected
cells. The difference between results obtained from the
g l o b a lS C D 1K Om o u s ea n dt h ep r e s e n tr e s u l t sm a yb e
explained by experiences from the SCD1 skin-specific
knockout (SKO) mouse [22], which is also resistant to
diet-induced obesity. The SKO mouse has increased
thermogenesis due to a damaged skin barrier and has
reduced expression of lipogenic genes in the liver sug-
gesting that the beneficial phenotype in the global
knockout may at least partly depend on enhanced heat
loss in these animals. The cellular response to ablation
of SCD1 also seems to be tissue dependent. Cardiomyo-
cytes from the SCD1 KO mouse have inhibited fatty
acid oxidation and increased glucose utilization [23],
while primary mouse hepatocytes transfected with anti-
sense oligonucleotides towards SCD1 show decreased
fatty acid synthesis and increased oxidation [8]. Also,
white adipose tissue from the SCD1 KO mouse displays
lower levels of inflammation and improved insulin sig-
naling [24]. Since both hepatocytes and adipocytes are
major players in lipogenesis, it could be postulated that
the positive effects of SCD1 reduction or removal is pri-
marily linked to lipogenic tissues.
To explore what effects reduced levels of SCD1 had in
insulin-producing b-cells, we protein profiled cells with
reduced and control SCD1 levels. In the SCD1 KD cells,
levels of chaperones and proteasomal components were
up-regulated, indicating increased capacity of the ER to
handle client proteins. When cells were challenged with
the fatty acid palmitate, rather than being protected
from ER stress, they exhibited increased levels of p-
eIF2a, CHOP and cleaved caspase-3, however. SCD1 is
the enzyme responsible for conversion of the saturated
fatty acid palmitate to its monounsaturated counterpart
palmitoleate. Since exposure to palmitoleate does not
elicit ER stress [25], the disruption in ER homeostasis
may be accentuated in SCD1 KD cells exposed to palmi-
tate. In agreement with this, it was shown that human
myotubes have an inverse correlation between the sus-
ceptibility to develop palmitate-induced ER stress and
the levels of SCD1 [7]. The b-cell has been shown to be
particularly sensitive to ER stress, probably due to its
high synthesis of insulin [26]. The phenomenon of
enhanced sensitivity to ER stress in SCD1 KD cells may
Table 1 Cellular proteins differentially regulated by SCD1
knockdown
Protein SCD1 KD
Rho GDP dissociation inhibitor (GDI) a 36% up
Prolyl 4-hydroxylase, b 80% up
GRP94 64% up
Proteasome subunit a type 3 52% up
Proteasome 26 S subunit 75% up
Heterogeneous nuclear ribonucleoprotein H1 46% up
Protein disulfide isomerase associated 3 78% up
Nucleosome assembly protein 136% up
Seryl-aminoacyl-tRNA synthetase 93% up
Nucleolysin TIAR 144% up
Phosphoserine aminotransferase 1 73% up
MIN6 cells were transfected with siRNA targeted towards SCD1 or with
nonsense siRNA (mock). After 72 hours culture, cellular proteins were isolated
and subjected to 2D-gel electrophoresis. After staining, differentially expressed
proteins were cut and identified using peptide mass fingerprint. Differences
indicate change induced by reduction in SCD1 levels. Results are means of 4
independent experiments. Significantly different (P < 0.05) expressed proteins
in SCD1 KD cells compared with mock transfected cells are shown.
Figure 2 Levels of p-eIF2a,C H O Pa n dc l e a v e dc a s p a s e - 3i n
MIN6 cells with reduced SCD1 levels. MIN6 cells were transfected
with siRNA targeted towards SCD1 (black bar) or with nonsense
siRNA (mock; white bar). After 72 hours culture, protein levels of p-
eIF2a, CHOP and cleaved caspase-3 were measured. Results are
means ± SEM from 4-6 individual experiments. *P < 0.05 denotes
difference compared to mock-transfected cells.
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down levels of SCD1 in HeLa cells causes increased ER
stress and induction of apoptosis [27]. It was postulated
that the negative effects of SCD1 inhibition is mediated
via the pro-inflammatory action of saturated fatty acid
species such as palmitate, which accumulate after SCD1
inhibition [28]. In agreement with this hypothesis, inclu-
sion of anti-inflammatory ω3 poly-unsaturated fatty
acids (PUFA) prevented not only deleterious effects of
SCD1 inhibition [28], but also palmitate-induced apop-
tosis [29]. Thus, supplementation of ω3-PUFA in con-
junction with inhibition of SCD1 may provide a useful
strategy to avoid the negative effects of SCD1 inhibition.
Conclusions
In summary, our data suggest that reducing the levels of
SCD1 in the b-cell augments the effect of palmitate on
ER stress and apoptosis. The findings may have implica-
tions to situations with increased circulating lipids and
should be taken into consideration when targeting
SCD1 as a treatment of the metabolic syndrome.
Methods
Cell culture
Mouse MIN6 cells, a kind gift from Professor Jun-Ichi
Miyazaki, Osaka University, were maintained in DMEM
supplemented with 15% FBS, 100 units/ml of penicillin,
100 μg/ml streptomycin (all from Invitrogen, Carlsbad,
CA) and 50 μM b-mercaptoethanol at 37°C and 5%
CO2. All experiments with MIN6 cells were performed
between passages 21 and 28. During fatty acid (FA)
exposure 0.5% FA-free BSA (Boehringer Mannheim
GmbH, Mannheim, Germany) was added.
Knockdown of SCD1 mRNA
MIN6 cells were reverse transfected with pooled siRNA
from Invitrogen and Ambion (Ambion, Austin, TX),
each at 50 nM or with mock siRNA from Ambion at
100 nM in an antibiotic free media using Lipofectamine
2000 (Invitrogen) according to manufacturer’si n s t r u c -
tions. After 24 hours, the media was changed and the
cells were treated as indicated.
Fatty acid preparation and cell treatment
Stock solutions containing palmitate (Sigma P-9767, St.
Louis, MO) were prepared by dissolving the fatty acid in
50% ethanol to a final concentration of 100 mM. The
stock solution was then diluted in culture medium with
0.5% FA-free BSA (Boehringer Mannheim GmbH) to a
final concentration of 0.25 mM. Cells were cultured to
60-70% confluence and exposed to the fatty acid for up
to 48 hours.
Figure 3 Levels of markers of ER stress and apoptosis in SCD1 KD and mock-transfected MIN6 cells after palmitate exposure. MIN6
cells were transfected with siRNA targeted towards SCD1 (black square) or with nonsense siRNA (mock; white square) and cultured for the
indicated time periods in the presence of 0.25 mM palmitate. After culture, protein levels of p-eIF2a (panel A), CHOP (panel B), and cleaved
caspase-3 (panel C) were measured. Results are means ± SEM from 3-6 individual experiments. *P < 0.05 denotes effect of SCD1 KD compared
to mock-transfected cells at indicated time point and #P < 0.05 denotes effect of palmitate compared to time 0.
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Total RNA were isolated from MIN6 cells using the
ChargeSwitch Total Cell RNA kit (Invitrogen) according
to manufacturer’s instructions and reverse transcribed
with SuperScript™ III First-Strand Synthesis System for
RT-PCR (Invitrogen) using Oligo-dT primers. The real-
time PCR was performed in 10 μl volume containing
~20 ng RNA equivalent, 0.5 μM forward and reverse
primers and 5 μl Dynamo Capillary SYBR green qPCR
k i t( F i n n z y m e s ,E s p o o ,F i n l a nd). Primers used for the
amplification are shown in Table 2. PCR products were
quantified fluorometrically using SYBR Green, and nor-
malized to the housekeeping gene b-actin and relative
to the control according to the following formula: target
amount = 2
-ΔΔCt,w h e r eΔΔCt ={ [ Ct (target gene) - Ct
(b-actin)] - [Ct (control) - Ct (b-actin control)}.
Separation and identification of proteins
Proteins obtained from cells with reduced or control
SCD1 levels were solubilized, separated, quantified and
identified essentially as described recently [30]. In short,
MIN6 cells were lysed in buffer containing 1% Triton
X-100, 1% SDS and protease inhibitor cocktail, homoge-
nized by sonication and re-suspended in rehydration
solution for the iso-electric focusing (IEF). The solution
was composed of 7 M urea, 2 M thiourea, 0.5% Triton
X-100, 4% CHAPS, 0.5% pharmalyte (pH 3-10), 0.1%
NP-7 and 60 mM DTT. Protein concentration was
determined (2-D Quant Kit, GE Healthcare, Uppsala,
Sweden). Individual 11-cm immobilized pH gradient
(IPG) strips, pH 3-10 NL (Bio-Rad, Hercules, CA) were
rehydrated with samples followed by protein focusing
(Protean IEF Cell, Bio-Rad). Focused proteins were
r e d u c e da n da l k y l a t e da n dS D S - P A G Ew a sp e r f o r m e d
on 12.5% precast polyacrylamide gels (Bio-Rad). Proteins
were stained with Pageblue (Fermentas, Vilnius, Lithua-
nia) overnight, quantified (GS-800-calibrated densit-
ometer, Bio-Rad) and analyzed including determination
of molecular weight and pI for the individual proteins
(PDQuest Advanced 8.0.1, Bio-Rad). Proteins were iden-
tified by excision of spots followed by in-gel digestion
with trypsin. Peptide masses were determined by mass
spectrometry (MALDI-TOF MS) at the Wallenberg
Consortium North Expression Proteomics Facility
(Department of Medical Biochemistry and Microbiology,
Uppsala University, Sweden) and proteins identified
based on peptide masses.
Western blot analysis
Samples for western blotting were prepared from MIN6
cells by washing the cells twice with PBS followed by
lysing the cells on ice with a buffer composed of
150 mM NaCl, 20 mM Tris, 1% Triton X100, 0.25% Na-
deoxycholate, 0.1% SDS, 1 mM Na3VO4,2m ME D T A
and 1% protease inhibitor cocktail (Sigma P-8340) for
30 min. After lysis the preparations were collected and
centrifuged at 13000 rpm for 15 min at 4°C. The super-
natants were transferred to new tubes and the total pro-
tein concentration was determined by the DC protein
assay (Bio-Rad) according to the manufacturer’s instruc-
tion. Samples were mixed with SDS-PAGE sample buf-
fer containing Tris-HCl (pH 6.8), SDS, glycerol and
DTT and boiled for 5 min. Samples (25 μg per well)
were then subjected to SDS-PAGE. After electrophor-
esis, proteins were transferred onto PVDF membranes.
Immunoblot analyses were performed with antibodies
towards phosphorylated eIF2a (Cell Signaling, Beverly,
MA), phosphorylated AMPK (Cell Signaling), cleaved
caspase-3 (Cell Signaling) and CHOP (Santa Cruz Bio-
technology, Santa Cruz, CA). Immuno-reactive bands
were imaged with Fluor-S MultiImager MAX (Bio-Rad)
and quantified with Quantity One software (Bio-Rad).
After imaging the PVDF membranes were stained with
Coomassie and later de-stained with 50% methanol. The
blots were then scanned in a standard table-top scanner
and quantified with Quantity One software. The expres-
sion level of each protein was normalized to the Coo-
massie-stained blot.
Fatty acid oxidation measurements
Reaction mixture was prepared by adding 2 μCi
3H-pal-
mitate (GE Healthcare) per ml culture media containing
0.5% fatty acid-free BSA. Unlabelled palmitate was
added to make the final concentration 0.25 mM. MIN6
cells exposed to fatty acids or not were washed with
PBS. Cells were then incubated for 2 hours with the
reaction mixture after which the media was collected.
Radioactive water was separated from the radioactive
palmitate in the media by three subsequent Folch
extractions [31]. During extraction, proteins were iso-
lated from the cells and the concentration was mea-
sured. After the last extraction, 10 ml scintillation liquid
was mixed with the water phase and the mixture was
counted in a scintillation counter. The results were nor-
malized to protein amount in the corresponding wells.
Glucose-stimulated insulin secretion
Glucose-stimulated insulin secretion (GSIS) was deter-
mined in MIN6 cells with reduced or control SCD1
levels. The cells were first incubated for 60 min in stan-
dard culture medium but with 2 mM glucose. Subse-
quently the medium was changed to KRBH buffer
Table 2 Primers used for real-time PCR
Target Forward primer Reverse primer
b-actin GTTACAGGAAGTCCCTCACC GGAGACCAAAGCCTTCATAC
SCD1 CTTCTTGCGATACACTCTGG TGAATGTTCTTGTCGTAGGG
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MgSO4 1.2, KH2PO4 1.2, CaCl2 2.5, NaHCO3 5.0, and
HEPES 10, titrated to pH 7.4 with NaOH and supple-
mented with 1 mg/ml of BSA (fraction V, Boehringer
Mannheim GmbH). The cells were allowed to rest for
30 min before medium was changed to the same type of
buffer but with either 2 or 20 mM glucose. The cells
were then incubated for 30 min. After incubation an ali-
quot of buffer was taken for later determination of
released insulin. Cells were then washed in PBS, lysed in
MilliQ H2O, and frozen for later determination of DNA
content. Released insulin was determined with an ELISA
as previously described [32].
Data analysis
Results are presented as means ± SEM. Statistical signif-
icance between two conditions was analyzed by the Stu-
dent’sp a i r e dt test and between several groups using
one-way ANOVA with Tukey post-hoc test. P <0 . 0 5
was considered statistically significant.
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